section name header

Evidence summaries

Riociguat for Pulmonary Hypertension

Riociguat appears to improve pulmonary artery pressures and exercise capacity in people with pulmonary artery hypertension (PAH) who are treatment naive or receiving a prostanoid or endothelin antagonist or those with recurrent or inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Level of evidence: "B"

The quality of evidence is downgraded by imprecice results (few patients).

Summary

A Cochrane review [Abstract] included 5 studies with a total of 962 adults diagnosed with pulmonary hypertension. The aetiology of pulmonary hypertension varied and included pulmonary artery hypertension (PAH, 2 studies), chronic thromboembolic pulmonary hypertension (CTEPH, 1 study) and left-sided heart failure subjects (2 studies). All studies were of relatively short duration (< 16 weeks). Four studies compared a soluble guanylate cyclase (sGC) stimulator riociguat with placebo and 1 study randomised patients receiving a phosphodiesterase-V inhibitor (sildenafil) to placebo or riociguat.

Overall, riociguat increased six-minute walking distance (6MWD) (MD 30.13 metres, 95% CI 5.29 to 54.96 metres, statistical heterogeneity I2 =64%; 3 studies, n=659). In patients with PAH there was no effect noted (MD 11.91 metres, 95% CI 44.92 to 68.75, statistical heterogeneity I2 =77%; 2 studies, n=398), and in CTEPH riociguat improved 6MWD (MD 45 metres, 95% CI 23.87 to 66.13 metres; 1 study, n=261). Data for left heart disease-associated PH was not available for pooling. When participants receiving phosphodiesterase inhibitors (sildenafil) were excluded, riosiguat increased 6MWD by a MD of 36 metres in PAH. The second primary outcome, mortality, showed no change on pooled analysis against placebo (Peto OR 0.57, 95% CI 0.18 to 1.80; 5 studies, n=899).

Pooled secondary outcomes included no statistically significant difference in World Health Organization (WHO) functional class (OR 1.53, 95% CI 0.87 to 2.72; 4 studies, n=858), no effect on clinical worsening (OR 0.45, 95% CI 0.17 to 1.14, statistical heterogeneity I2 =54%; 3 studies, n=842), and a reduction in mean pulmonary artery pressure (MD 2.77 mmHg, 95% CI 4.96 to 0.58; 5 studies, n=744). Reduction in mean pulmonary artery pressure was seen in patients with PAH (MD -3.5 mmHg, 95% CI -5.54 to -1.46; 1 study, n=344) and CTEPH (MD -4.8 mmHg, 95% CI -6.71 to -2.89; 1 study, n=240) but not in left heart disease.

There was no significant difference in serious adverse events on pooled analysis (OR 1.12, 95% CI 0.66 to 1.90; 5 studies, n=818) or when analysed at PAH (OR 0.93, 95% CI 0.22 to 3.83, statistical heterogeneity I2 = 53%; 2 studies, n=398), left heart disease associated subgroups (OR 1.56, 95% CI 0.78 to 3.13; 2 studies, n=159) or CTEPH subgroups (OR 1.29, 95% CI 0.65 to 2.56; 1 study, n=261).

Clinical comments

Soluble guanylate cyclase (sGC) stimulators should not be taken by people also receiving phosphodiestase-V inhibitors or nitrates due to the risks of hypotension. CTEPH results are applicable to inoperable or recurrent CTEPH only, and CTEPH should always be considered a surgically curable condition before reviewing medical therapy.

Note

Date of latest search:

References

  • Wardle AJ, Seager MJ, Wardle R et al. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database Syst Rev 2016;(8):CD011205. [PubMed]

Primary/Secondary Keywords